10x Genomics (NASDAQ: TXG) net income
10x Genomics reported a net loss of $43.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $182.6m. Earnings per share were −$0.35.
10x Genomics's best year of the last 8 was fiscal 2019. It reported a loss in 8 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$43.5m | — | −6.8% | −$0.35 |
| 2024 | −$182.6m | — | −29.9% | −$1.52 |
| 2023 | −$255.1m | — | −41.2% | −$2.18 |
| 2022 | −$166.0m | — | −32.1% | −$1.46 |
| 2021 | −$58.2m | — | −11.9% | −$0.53 |
| 2020 | −$542.7m | — | −181.6% | −$5.37 |
| 2019 | −$31.3m | — | −12.7% | −$0.80 |
| 2018 | −$112.5m | — | −76.9% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
10x Genomics net income compared with its sector
By net income for its latest fiscal year, 10x Genomics ranks 245th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of 10x Genomics, −6.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 243rd | Palvella Therapeutics | −$41.7m | — |
| 244th | Trevi Therapeutics | −$42.8m | — |
| 245th | 10x Genomics | −$43.5m | −6.8% |
| 246th | Codexis | −$44.0m | −62.5% |
| 247th | iRhythm | −$44.6m | −6.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of 10x Genomics
- How much did 10x Genomics earn in fiscal 2025?
- 10x Genomics reported a net loss of $43.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $182.6m.
- What are the earnings per share of 10x Genomics?
- They were −$0.35 in fiscal 2025, compared with −$1.52 in fiscal 2024.
- Where does 10x Genomics rank in its sector by net income?
- It ranks 245th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for 10x Genomics come from?
- From the annual report (Form 10-K) that 10x Genomics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that 10x Genomics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on 10x Genomics: the 10x Genomics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.